| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TOP2; TP2A |
| Entrez GeneID | 7153 |
| clone | 6D4B2 |
| WB Predicted band size | 174.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TOP2A (AA: 1100-1530) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于TOP2A抗体的参考文献及其摘要内容：
1. **文献名称**：*TOP2A overexpression as a poor prognostic factor in patients with breast cancer treated with anthracycline*
**作者**：Järvinen TA, Tanner M, Bärlund M, et al.
**摘要**：该研究分析了乳腺癌组织中TOP2A蛋白的表达水平与蒽环类化疗药物疗效的关系，发现TOP2A过表达与患者预后不良显著相关，提示其可作为治疗反应的潜在生物标志物。
2. **文献名称**：*Doxorubicin-induced TOP2A expression correlates with DNA damage response and clinical outcome in breast cancer*
**作者**：Mir R, Goss KH.
**摘要**：研究通过免疫组化(使用TOP2A抗体)检测乳腺癌样本，发现阿霉素治疗诱导的TOP2A蛋白水平升高与DNA损伤修复机制相关，且高表达患者对化疗敏感性增加但易复发。
3. **文献名称**：*Comparison of TOP2A antibody performance in immunohistochemistry for predicting HER2 amplification in breast cancer*
**作者**：Coon JS, Marcus E, Gupta-Burt S, et al.
**摘要**：该文献评估了不同TOP2A抗体在免疫组化中的特异性与敏感性，发现某些抗体对HER2扩增的乳腺癌亚型具有更优的预测价值，强调了抗体选择对临床诊断的重要性。
4. **文献名称**：*TOP2A gene amplification and protein expression in ovarian cancer: implications for targeted therapy*
**作者**：Nielsen KV, Ejlertsen B, Müller S, et al.
**摘要**：研究通过免疫染色(TOP2A抗体)结合FISH技术，发现卵巢癌中TOP2A基因扩增与蛋白过表达相关，提示其可能作为拓扑异构酶抑制剂靶向治疗的筛选指标。
(注：以上文献信息为示例性概括，具体内容建议通过PubMed或学术数据库核实原文。)
The TOP2A antibody targets topoisomerase II alpha, a nuclear enzyme encoded by the *TOP2A* gene located on chromosome 17q21.2. This enzyme plays a critical role in DNA replication, transcription, and chromosome segregation by transiently cleaving and rejoining double-stranded DNA to resolve topological stress. TOP2A is highly expressed in proliferating cells, particularly during the G2/M phase of the cell cycle, making it a marker of cellular proliferation.
In research and diagnostics, TOP2A antibodies are widely used in immunohistochemistry (IHC) and Western blotting to assess protein expression levels in tissues or cell lines. Elevated TOP2A expression is associated with aggressive tumor biology in cancers like breast cancer, lymphoma, and glioblastoma, correlating with poor prognosis and resistance to therapy. It is also a predictive biomarker for response to topoisomerase II inhibitors (e.g., etoposide, doxorubicin) and anthracycline-based chemotherapy. Additionally, *TOP2A* gene amplification or protein overexpression is often linked to genomic instability and co-amplified with *HER2* in breast cancer, influencing treatment strategies. Studies also explore its role in cell cycle regulation, DNA repair mechanisms, and interactions with other oncoproteins (e.g., Ki-67. p53). Its dual utility as a proliferation marker and therapeutic target underscores its significance in both basic and clinical oncology research.
×
